**Amendments to the Claims:**

This claim listing replaces all prior versions, and listings of claims in the application.

Please amend the claims as follows:

1. (Currently amended) Compounds of the general formula




(I)

wherein




is a group of one of the formulae




(a1)




(a2)



(b1) (b2) c1)



(c2) (c3) (d)



(e1) (e2) (e3)



(e4) (f) (g)



(h) (i1) (i2)



(i3) (i4) (j)



(k) (l) (m)



(n) (o) and (p)

wherein



is the residue of an L-α-amino acid with B being a residue of formula $-NR^{20}CH(R^{71})-$ or the enantiomer of one of the groups **A1** to **A69** as defined hereinafter;

is a group of one of the formulae



**A1** **A2** **A3** **A4**



**A5** **A6** **A7** **A8** **A9**



A10 A11 A12 A13 A14



A15 A16 A17 A18 A19



A20 A21 A22 A23 A24



A25 A26 A27 A28



A29 A30 A31 A32 A33



A34 A35 A36 A37



A38 A39 A40 A41 A42



A43 A44 A45 A46 A47



A48 A49 A50 A51 A52



A53 A54 A55 A56 A57



A58 A59 A60 A61 A62



A63 A64 A65 A66



A67 A68 A69



A70 A71 A72 A73 A74



A75 A76 A77 A78 A79



A80 A81 A82 A83 A84



A85 A86 A87 A88 A89



A90 A91 A92 A93 A94



A95 A96 A97 A98 A99




A100 A101 A102 A103 A104

$R^1$ is H; lower alkyl; or aryl-lower alkyl;

$R^2$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$; $-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_s\ SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;

$R^3$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$; $-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$ ; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_s\ SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;

$R^4$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$; $-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_p(CHR^{61})_sCOOR^{57}$; $-(CH_2)_p(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_p(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_p(CHR^{61})_s\ SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;

$R^5$ is alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_s\ SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;

$R^6$ is H; alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_s SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;

$R^7$ is alkyl; alkenyl; $-(CH_2)_q(CHR^{61})_sOR^{55}$; $-(CH_2)_q(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_q(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_q(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_r(CHR^{61})_sCOOR^{57}$; $-(CH_2)_r(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_r(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_r(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_r(CHR^{61})_s C_6H_4R^8$;

$R^8$ is H; Cl; F; $CF_3$; $NO_2$; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})NR^{33}R^{34}$ ; $-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sCOR^{64}$;

~~$R^9$ is alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_s SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{10}$ is alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_s SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

$R^{11}$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_s C_6H_4R^8$;

$R^{12}$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$;

$-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;

$-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_r(CHR^{61})_sCOOR^{57}$;

$-(CH_2)_r(CHR^{61})_sCONR^{58}R^{59}$;

$-(CH_2)_r(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_r(CHR^{61})_s SO_2R^{62}$; or $-(CH_2)_r(CHR^{61})_sC_6H_4R^8$;

~~$R^{13}$ is alkyl; alkenyl; $(CH_2)_q(CHR^{61})_sOR^{55}$; $(CH_2)_q(CHR^{61})_sSR^{56}$; $(CH_2)_q(CHR^{61})_sNR^{33}R^{34}$;~~

~~$(CH_2)_q(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_q(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$(CH_2)_q(CHR^{61})_sCOOR^{57}$; $(CH_2)_q(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_q(CHR^{61})_sPO(OR^{60})_2$;~~

~~$(CH_2)_q(CHR^{61})_s SO_2R^{62}$; or $(CH_2)_q(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{14}$ is H; alkyl; alkenyl; $(CH_2)_m(CHR^{61})_sOR^{55}$; $(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$;~~

~~$(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$(CH_2)_q(CHR^{61})_sCOOR^{57}$; $(CH_2)_q(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_q(CHR^{61})_sPO(OR^{60})_2$;~~

~~$(CH_2)_q(CHR^{61})_sSOR^{62}$; or $(CH_2)_q(CHR^{61})_s C_6H_4R^8$;~~

~~$R^{15}$ is alkyl; alkenyl; $(CH_2)_o(CHR^{61})_sOR^{55}$; $(CH_2)_o(CHR^{61})_sSR^{56}$; $(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$;~~

~~$(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$(CH_2)_o(CHR^{61})_sCOOR^{57}$; $(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;~~

~~$(CH_2)_o(CHR^{61})_s SO_2R^{62}$; or $(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{16}$ is alkyl; alkenyl; $(CH_2)_o(CHR^{61})_sOR^{55}$; $(CH_2)_o(CHR^{61})_sSR^{56}$; $(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$;~~

~~$(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$(CH_2)_o(CHR^{61})_sCOOR^{57}$; $(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;~~

~~$(CH_2)_o(CHR^{61})_s SO_2R^{62}$; or $(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{17}$ is alkyl; alkenyl; $(CH_2)_q(CHR^{61})_sOR^{55}$; $(CH_2)_q(CHR^{61})_sSR^{56}$; $(CH_2)_q(CHR^{61})_sNR^{33}R^{34}$;~~

~~$(CH_2)_q(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_q(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$(CH_2)_q(CHR^{61})_sCOOR^{57}$; $(CH_2)_q(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_q(CHR^{61})_sPO(OR^{60})_2$;~~

~~$(CH_2)_q(CHR^{61})_s SO_2R^{62}$; or $(CH_2)_q(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{18}$ is alkyl; alkenyl; $(CH_2)_p(CHR^{61})_sOR^{55}$; $(CH_2)_p(CHR^{61})_sSR^{56}$; $(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$;~~

~~$(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$(CH_2)_p(CHR^{61})_sCOOR^{57}$; $(CH_2)_p(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_p(CHR^{61})_sPO(OR^{60})_2$;~~

~~$-(CH_2)_p(CHR^{61})_s-SO_2R^{62}$; or $-(CH_2)_e(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{19}$ is lower alkyl; $-(CH_2)_p(CHR^{61})_sOR^{55}$; $-(CH_2)_p(CHR^{61})_sSR^{56}$; $-(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$;~~

~~$-(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$-(CH_2)_p(CHR^{61})_sCOOR^{57}$; $-(CH_2)_p(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_p(CHR^{61})_sPO(OR^{60})_2$;~~

~~$-(CH_2)_p(CHR^{61})_s-SO_2R^{62}$; or $-(CH_2)_e(CHR^{61})_sC_6H_4R^8$; or~~

~~$R^{18}$ and $R^{19}$ taken together can form: $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or~~

~~$-(CH_2)_2NR^{57}(CH_2)_2-$;~~

$R^{20}$ is H; alkyl; alkenyl; or aryl-lower alkyl;

~~$R^{21}$ is H; alkyl; alkenyl; $-(CH_2)_e(CHR^{61})_sOR^{55}$; $-(CH_2)_e(CHR^{61})_sSR^{56}$;~~

~~$-(CH_2)_e(CHR^{61})_sNR^{33}R^{34}$;~~

~~$-(CH_2)_e(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_e(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$-(CH_2)_e(CHR^{61})_sCOOR^{57}$; $-(CH_2)_e(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_e(CHR^{61})_sPO(OR^{60})_2$;~~

~~$-(CH_2)_e(CHR^{61})_s-SO_2R^{62}$; or $-(CH_2)_e(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{22}$ is H; alkyl; alkenyl; $-(CH_2)_e(CHR^{61})_sOR^{55}$; $-(CH_2)_e(CHR^{61})_sSR^{56}$;~~

~~$-(CH_2)_e(CHR^{61})_sNR^{33}R^{34}$;~~

~~$-(CH_2)_e(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_e(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$-(CH_2)_e(CHR^{61})_sCOOR^{57}$; $-(CH_2)_e(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_e(CHR^{61})_sPO(OR^{60})_2$;~~

~~$-(CH_2)_e(CHR^{61})_s-SO_2R^{62}$; or $-(CH_2)_e(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{23}$ is alkyl; alkenyl; $-(CH_2)_e(CHR^{61})_sOR^{55}$; $-(CH_2)_e(CHR^{61})_sSR^{56}$; $-(CH_2)_e(CHR^{61})_sNR^{33}R^{34}$;~~

~~$-(CH_2)_e(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_e(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$-(CH_2)_e(CHR^{61})_sCOOR^{57}$; $-(CH_2)_e(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_e(CHR^{61})_sPO(OR^{60})_2$;~~

~~$-(CH_2)_e(CHR^{61})_s-SO_2R^{62}$; or $-(CH_2)_e(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{24}$ is alkyl; alkenyl; $-(CH_2)_e(CHR^{61})_sOR^{55}$; $-(CH_2)_e(CHR^{61})_sSR^{56}$; $-(CH_2)_e(CHR^{61})_sNR^{33}R^{34}$;~~

~~$-(CH_2)_e(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_e(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$-(CH_2)_e(CHR^{61})_sCOOR^{57}$; $-(CH_2)_e(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_e(CHR^{61})_sPO(OR^{60})_2$;~~

~~$-(CH_2)_e(CHR^{61})_s-SO_2R^{62}$; or $-(CH_2)_e(CHR^{61})_sC_6H_4R^8$;~~

$R^{25}$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$;

$-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;
$-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$;
$-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;
$-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;

$R^{26}$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$;
$-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;
$-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$;
$(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$;
$-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$; $-(CH_2)_o(CHR^{61})_s SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$; or

$R^{25}$ and $R^{26}$ taken together can form: $-(CH_2)_{2\text{-}6}$-; $-(CH_2)_rO(CH_2)_r$-; $-(CH_2)_rS(CH_2)_r$-; or
$-(CH_2)_rNR^{57}(CH_2)_r$-;

~~$R^{27}$ is H; alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$;~~
~~$-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$;~~
~~$-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$;~~
~~$-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;~~
~~$-(CH_2)_o(CHR^{61})_s SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{28}$ is alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_s OR^{55}$; $-(CH_2)_o(CHR^{61})_s SR^{56}$; $-(CH_2)_o(CHR^{61})_s NR^{33}R^{34}$;~~
~~$-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$-(CH_2)_o(CHR^{61})_s COOR^{57}$; $-(CH_2)_o(CHR^{61})_s CONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_s PO(OR^{60})_2$;~~
~~$-(CH_2)_o(CHR^{61})_s SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_s C_6H_4R^8$;~~

~~$R^{29}$ is alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_o(CHR^{61})_sSR^{56}$; $-(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$;~~
~~$-(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;~~
~~$-(CH_2)_o(CHR^{61})_s SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{30}$ is H; alkyl; alkenyl; or aryl-lower alkyl;~~

~~$R^{31}$ is H; alkyl; alkenyl; $-(CH_2)_p(CHR^{61})_sOR^{55}$; $-(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$;~~
~~$-(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~

~~$-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;~~
~~$-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{32}$ is H; lower alkyl; or aryl-lower alkyl;~~

$R^{33}$ is H; alkyl, alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sNR^{34}R^{63}$;
$-(CH_2)_m(CHR^{61})_sOCONR^{75}R^{82}$; $-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{78}R^{82}$;
$-(CH_2)_o(CHR^{61})_sCOR^{64}$; $-(CH_2)_o(CHR^{61})_s$-$CONR^{58}R^{59}$, $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;
$-(CH_2)_o(CHR^{61})_s SO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;

$R^{34}$ is H; lower alkyl; aryl, or aryl-lower alkyl;

$R^{33}$ and $R^{34}$ taken together can form: $-(CH_2)_{2\text{-}6}$-; $-(CH_2)_2O(CH_2)_2$-; $-(CH_2)_2S(CH_2)_2$-; or
$-(CH_2)_2NR^{57}(CH_2)_2$-;

~~$R^{35}$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$;~~
~~$-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$-(CH_2)_p(CHR^{61})_sCOOR^{57}$; $-(CH_2)_p(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_p(CHR^{61})_sPO(OR^{60})_2$;~~
~~$-(CH_2)_p(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_p(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{36}$ is H, alkyl; alkenyl; $-(CH_2)_o(CHR^{61})_sOR^{55}$; $-(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$;~~
~~$-(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$-(CH_2)_p(CHR^{61})_sCOOR^{57}$; $-(CH_2)_p(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_p(CHR^{61})_sPO(OR^{60})_2$;~~
~~$-(CH_2)_p(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

$R^{37}$ is H; F; Br; Cl; $NO_2$; $CF_3$; lower alkyl; $-(CH_2)_p(CHR^{61})_sOR^{55}$; $-(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$;
$-(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;
$-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;
$-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_s C_6H_4R^8$;

~~$R^{38}$ is H; F; Br; Cl; $NO_2$; $CF_3$; alkyl; alkenyl; $-(CH_2)_p(CHR^{61})_sOR^{55}$; $-(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$;~~
~~$-(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$-(CH_2)_o(CHR^{61})_sCOOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;~~
~~$-(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $-(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{39}$ is H; alkyl; alkenyl; or aryl-lower alkyl;~~

~~$R^{40}$ is H; alkyl; alkenyl; or aryl-lower alkyl;~~

~~$R^{41}$ is H; F; Br; Cl; $NO_2$; $CF_3$; alkyl; alkenyl; $(CH_2)_p(CHR^{61})_sOR^{55}$; $(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$;~~
~~$(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$(CH_2)_o(CHR^{61})_sCOOR^{57}$; $(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;~~
~~$(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{42}$ is H; F; Br; Cl; $NO_2$; $CF_3$; alkyl; alkenyl; $(CH_2)_p(CHR^{61})_sOR^{55}$; $(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$;~~
~~$(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$(CH_2)_o(CHR^{61})_sCOOR^{57}$; $(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;~~
~~$(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{43}$ is H; alkyl; alkenyl; $(CH_2)_m(CHR^{61})_sOR^{55}$; $(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$;~~
~~$(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$(CH_2)_o(CHR^{61})_sCOOR^{57}$; $(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_o(CHR^{61})_sPO(OR^{60})_2$;~~
~~$(CH_2)_o(CHR^{61})_sSO_2R^{62}$; or $(CH_2)_o(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{44}$ is alkyl; alkenyl; $(CH_2)_r(CHR^{61})_sOR^{55}$; $(CH_2)_r(CHR^{61})_sSR^{56}$; $(CH_2)_r(CHR^{61})_sNR^{33}R^{34}$;~~
~~$(CH_2)_r(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_r(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$(CH_2)_r(CHR^{61})_sCOOR^{57}$; $(CH_2)_r(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_r(CHR^{61})_sPO(OR^{60})_2$;~~
~~$(CH_2)_r(CHR^{61})_sSO_2R^{62}$; or $(CH_2)_r(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{45}$ is H; alkyl; alkenyl; $(CH_2)_o(CHR^{61})_sOR^{55}$; $(CH_2)_o(CHR^{61})_sSR^{56}$;~~
~~$(CH_2)_o(CHR^{61})_sNR^{33}R^{34}$;~~
~~$(CH_2)_o(CHR^{61})_sOCONR^{33}R^{75}$; $(CH_2)_o(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$(CH_2)_o(CHR^{61})_sCOOR^{57}$; $(CH_2)_s(CHR^{61})_sCONR^{58}R^{59}$; $(CH_2)_s(CHR^{61})_sPO(OR^{60})_2$;~~
~~$(CH_2)_s(CHR^{61})_sSO_2R^{62}$; or $(CH_2)_s(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{46}$ is H; alkyl; alkenyl; or $(CH_2)_o(CHR^{61})_pC_6H_4R^8$;~~

~~$R^{47}$ is H; alkyl; alkenyl; or $(CH_2)_o(CHR^{61})_sOR^{55}$;~~

~~$R^{48}$ is H; lower alkyl; lower alkenyl; or aryl-lower alkyl;~~

~~$R^{49}$ is H; alkyl; alkenyl; $(CHR^{61})_sCOOR^{57}$; $(CHR^{61})_sCONR^{58}R^{59}$; $(CHR^{61})_sPO(OR^{60})_2$;~~
~~$(CHR^{61})_sSOR^{62}$; or $(CHR^{61})_sC_6H_4R^8$;~~

$R^{50}$ is H; lower alkyl; or aryl-lower alkyl;

~~$R^{51}$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$;~~
~~$-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;~~
~~$-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$;~~
~~$-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_pPO(OR^{60})_2$;~~
~~$-(CH_2)_p(CHR^{61})_s-SO_2R^{62}$; or $-(CH_2)_p(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{52}$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$;~~
~~$-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;~~
~~$-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$;~~
~~$-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_pPO(OR^{60})_2$;~~
~~$-(CH_2)_p(CHR^{61})_s-SO_2R^{62}$; or $-(CH_2)_p(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{53}$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sSR^{56}$;~~
~~$-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$;~~
~~$-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$;~~
~~$-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{57}$;~~
~~$-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; $-(CH_2)_o(CHR^{61})_pPO(OR^{60})_2$;~~
~~$-(CH_2)_p(CHR^{61})_s-SO_2R^{62}$; or $-(CH_2)_p(CHR^{61})_sC_6H_4R^8$;~~

~~$R^{54}$ is H; alkyl; alkenyl; $-(CH_2)_m(CHR^{61})_sOR^{55}$; $-(CH_2)_m(CHR^{61})_sNR^{33}R^{34}$;~~
~~$-(CH_2)_m(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{33}R^{82}$;~~
~~$-(CH_2)_o(CHR^{61})COOR^{57}$; $-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$; or $-(CH_2)_o(CHR^{61})_s-C_6H_4R^8$;~~

$R^{55}$ is H; lower alkyl; lower alkenyl; aryl-lower alkyl; $-(CH_2)_m(CHR^{61})_sOR^{57}$;
$-(CH_2)_m(CHR^{61})_sNR^{34}R^{63}$; $-(CH_2)_m(CHR^{61})_sOCONR^{75}R^{82}$;
$-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{78}R^{82}$; $-(CH_2)_o(CHR^{61})_s-COR^{64}$; $-(CH_2)_o(CHR^{61})COOR^{57}$; or
$-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$;

$R^{56}$ is H; lower alkyl; lower alkenyl; aryl-lower alkyl; $-(CH_2)_m(CHR^{61})_sOR^{57}$;
$-(CH_2)_m(CHR^{61})_sNR^{34}R^{63}$; $-(CH_2)_m(CHR^{61})_sOCONR^{75}R^{82}$;
$-(CH_2)_m(CHR^{61})_sNR^{20}CONR^{78}R^{82}$; $-(CH_2)_o(CHR^{61})_s-COR^{64}$; or

$-(CH_2)_o(CHR^{61})_sCONR^{58}R^{59}$;

$R^{57}$ is H; lower alkyl; lower alkenyl; aryl lower alkyl; or heteroaryl lower alkyl;

$R^{58}$ is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl;

$R^{59}$ is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; or heteroaryl-lower alkyl; or

$R^{58}$ and $R^{59}$ taken together can form: $-(CH_2)_{2\text{-}6}$-; $-(CH_2)_2O(CH_2)_2$-; $-(CH_2)_2S(CH_2)_2$-; or $-(CH_2)_2NR^{57}(CH_2)_2$-;

$R^{60}$ is H; lower alkyl; lower alkenyl; aryl; or aryl-lower alkyl;

$R^{61}$ is alkyl; alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CH_2)_mOR^{55}$; $-(CH_2)_mNR^{33}R^{34}$; $-(CH_2)_mOCONR^{75}R^{82}$; $-(CH_2)_mNR^{20}CONR^{78}R^{82}$; $-(CH_2)_oCOOR^{37}$; $-(CH_2)_oNR^{58}R^{59}$; or $-(CH_2)_oPO(COR^{60})_2$;

$R^{62}$ is lower alkyl; lower alkenyl; aryl, heteroaryl; or aryl-lower alkyl;

$R^{63}$ is H; lower alkyl; lower alkenyl; aryl, heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-COR^{64}$; $-COOR^{57}$; $-CONR^{58}R^{59}$; $-SO_2R^{62}$; or $-PO(OR^{60})_2$;

$R^{34}$and $R^{63}$ taken together can form: $-(CH_2)_{2\text{-}6}$-; $-(CH_2)_2O(CH_2)_2$-; $-(CH_2)_2S(CH_2)_2$-; or $-(CH_2)_2NR^{57}(CH_2)_2$-;

$R^{64}$ is H; lower alkyl; lower alkenyl; aryl; heteroaryl; aryl-lower alkyl; heteroaryl-lower alkyl; $-(CH_2)_p(CHR^{61})_sOR^{65}$; $-(CH_2)_p(CHR^{61})_sSR^{66}$; or $-(CH_2)_p(CHR^{61})_sNR^{34}R^{63}$; $-(CH_2)_P(CHR^{61})_sOCONR^{75}R^{82}$; $-(CH_2)_P(CHR^{61})_sNR^{20}CONR^{78}R^{82}$;

$R^{65}$ is H; lower alkyl; lower alkenyl; aryl, aryl-lower alkyl; heteroaryl-lower alkyl; $-COR^{57}$; $-COOR^{57}$; or $-CONR^{58}R^{59}$;

$R^{66}$ is H; lower alkyl; lower alkenyl; aryl; aryl-lower alkyl; heteroaryl-lower alkyl; or $-CONR^{58}R^{59}$;

m is 2-4; o is 0-4; p is 1-4; q is 0-2; r is 1 or 2; s is 0 or 1;

Z is a chain of 12 α-amino acid residues, the positions of said amino acid residues in said chain being counted starting from the N-terminal amino acid, whereby these amino acid residues are, depending on their position in the chains, Gly, or Pro, or of formula -**A**-CO-, or of formula -**B**-CO-, or of one of the types

C: $-NR^{20}CH(R^{72})CO-$;

D: $-NR^{20}CH(R^{73})CO-$;

E: $-NR^{20}CH(R^{74})CO-$;

F: $-NR^{20}CH(R^{84})CO-$; and

H: $-NR^{20}-CH(CO-)-(CH_2)_{4-7}-CH(CO-)-NR^{20}-$;

$-NR^{20}-CH(CO-)-(CH_2)_pSS(CH_2)_p-CH(CO-)-NR^{20}-$;

$-NR^{20}-CH(CO-)-(-(CH_2)_pNR^{20}CO(CH_2)_p-CH(CO-)-NR^{20}-$; and

$-NR^{20}-CH(CO-)-(-(CH_2)_pNR^{20}CONR^{20}(CH_2)_p-CH(CO-)-NR^{20}-$;

I: $-NR^{86}CH_2CO-$;

K: $-NR^{87}CH_2CO-$;

$R^{71}$ is H; lower alkyl; lower alkenyl; $-(CH_2)_p(CHR^{61})_sOR^{75}$; $-(CH_2)_p(CHR^{61})_sSR^{75}$; $-(CH_2)_p(CHR^{61})_sNR^{33}R^{34}$; $-(CH_2)_p(CHR^{61})_sOCONR^{33}R^{75}$; $-(CH_2)_p(CHR^{61})_sNR^{20}CONR^{33}R^{82}$; $-(CH_2)_o(CHR^{61})_sCOOR^{75}$; $-(CH_2)_pCONR^{58}R^{59}$; $-(CH_2)_pPO(OR^{62})_2$; $-(CH_2)_pSO_2R^{62}$; ~~or~~ ~~$-(CH_2)_o-C_6R^{67}R^{68}R^{69}R^{70}R^{76}$;~~

$R^{72}$ is H, lower alkyl; lower alkenyl; $-(CH_2)_p(CHR^{61})_sOR^{85}$; or $-(CH_2)_p(CHR^{61})_sSR^{85}$;

$R^{73}$ is $-(CH_2)_oR^{77}$; $-(CH_2)_rO(CH_2)_oR^{77}$; $-(CH_2)_rS(CH_2)_oR^{77}$; or $-(CH_2)_rNR^{20}(CH_2)_oR^{77}$;

$R^{74}$ is $-(CH_2)_pNR^{78}R^{79}$; $-(CH_2)_pNR^{77}R^{80}$; $-(CH_2)_pC(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_pC(=NOR^{50})NR^{78}R^{79}$;

$-(CH_2)_pC(=NNR^{78}R^{79})NR^{78}R^{79}$; $-(CH_2)_pNR^{80}C(=NR^{80})NR^{78}R^{79}$;

$-(CH_2)_pN=C(NR^{78}R^{80})NR^{79}R^{80}$;$-(CH_2)_pC_6H_4NR^{78}R^{79}$; $-(CH_2)_pC_6H_4NR^{77}R^{80}$;

$-(CH_2)_pC_6H_4C(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_pC_6H_4C(=NOR^{50})NR^{78}R^{79}$;

$-(CH_2)_pC_6H_4C(=NNR^{78}R^{79})NR^{78}R^{79}$; $-(CH_2)_pC_6H_4NR^{80}C(=NR^{80})NR^{78}R^{79}$;
$-(CH_2)_pC_6H_4N=C(NR^{78}R^{80})NR^{79}R^{80}$; $-(CH_2)_rO(CH_2)_mNR^{78}R^{79}$; $-(CH_2)_rO(CH_2)_mNR^{77}R^{80}$;
$-(CH_2)_rO(CH_2)_pC(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_rO(CH_2)_pC(=NOR^{50})NR^{78}R^{79}$;
$-(CH_2)_rO(CH_2)_pC(=NNR^{78}R^{79})NR^{78}R^{79}$; $-(CH_2)_rO(CH_2)_mNR^{80}C(=NR^{80})NR^{78}R^{79}$;
$-(CH_2)_rO(CH_2)_mN=C(NR^{78}R^{80})NR^{79}R^{80}$; $-(CH_2)_rO(CH_2)_pC_6H_4CNR^{78}R^{79}$;
$-(CH_2)_rO(CH_2)_pC_6H_4C(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_rO(CH_2)_pC_6H_4C(=NOR^{50})NR^{78}R^{79}$;
$-(CH_2)_rO(CH_2)_pC_6H_4C(=NNR^{78}R^{79})NR^{78}R^{79}$;
$-(CH_2)_rO(CH_2)_pC_6H_4NR^{80}C(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_rS(CH_2)_mNR^{78}R^{79}$;
$-(CH_2)_rS(CH_2)_mNR^{77}R^{80}$;$-(CH_2)_rS(CH_2)_pC(=NR^{80})NR^{78}R^{79}$;
$-(CH_2)_rS(CH_2)_pC(=NOR^{50})NR^{78}R^{79}$; $-(CH_2)_rS(CH_2)_pC(=NNR^{78}R^{79})NR^{78}R^{79}$;
$-(CH_2)_rS(CH_2)_mNR^{80}C(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_rS(CH_2)_mN=C(NR^{78}R^{80})NR^{79}R^{80}$;
$-(CH_2)_rS(CH_2)_pC_6H_4CNR^{78}R^{79}$; $-(CH_2)_rS(CH_2)_pC_6H_4C(=NR^{80})NR^{78}R^{79}$;
$-(CH_2)_rS(CH_2)_pC_6H_4C(=NOR^{50})NR^{78}R^{79}$; $-(CH_2)_rS(CH_2)_pC_6H_4C(=NNR^{78}R^{79})NR^{78}R^{79}$;
$-(CH_2)_rS(CH_2)_pC_6H_4NR^{80}C(=NR^{80})NR^{78}R^{79}$; $-(CH_2)_pNR^{80}COR^{64}$; $-(CH_2)_pNR^{80}COR^{77}$;
$-(CH_2)_pNR^{80}CONR^{78}R^{79}$; or $-(CH_2)_pC_6H_4NR^{80}CONR^{78}R^{79}$;

$R^{75}$ is lower alkyl; lower alkenyl; or aryl-lower alkyl;

$R^{33}$ and $R^{75}$ taken together can form: $-(CH_2)_{2\text{-}6}$-; $-(CH_2)_2O(CH_2)_2$-; $-(CH_2)_2S(CH_2)_2$-; or
$-(CH_2)_2NR^{57}(CH_2)_2$-;

$R^{75}$ and $R^{82}$ taken together can form: $-(CH_2)_{2\text{-}6}$-; $-(CH_2)_2O(CH_2)_2$-; $-(CH_2)_2S(CH_2)_2$-; or
$-(CH_2)_2NR^{57}(CH_2)_2$-;

$R^{76}$ is H; lower alkyl; lower alkenyl; aryl-lower alkyl; $-(CH_2)_oOR^{72}$; $-(CH_2)_oSR^{72}$;
$-(CH_2)_oNR^{33}R^{34}$; $-(CH_2)_oOCONR^{33}R^{75}$; $-(CH_2)_oNR^{20}CONR^{33}R^{82}$;
$-(CH_2)_oCOOR^{75}$; $-(CH_2)_oCONR^{58}R^{59}$; $-(CH_2)_oPO(OR^{60})_2$; $-(CH_2)_pSO_2R^{62}$; or
$-(CH_2)_oCOR^{64}$;

$R^{77}$ is ~~$-C_6R^{67}R^{68}R^{69}R^{70}R^{76}$;~~ is phenyl, p-hydroxyphenyl, 2-naphthyl, 1-naphthyl, 4-chlorophenyl, 3-chlorophenyl, 2-chlorophenyl, 3,4-dichlorophenyl, 4-fluorophenyl, 3-

fluorophenyl, 2-fluorophenyl, p-benzyloxyphenyl, p-biphenyl or p-benzoylphenyl or a heteroaryl group of one of the formulae



**H1**



**H2**



**H3**



**H4**



**H5**



**H6**



**H7**



**H8**



**H9**



**H10**



**H11**



**H12**



**H13**



**H14**



**H15**



**H16**



**H17**



**H18**



**H19**



**H20**



**H21**



**H22**



**H23**



**H24**



**H25**



**H26**



**H27**



**H28**



**H29**




H30




H31




H32




H33




H34




H35




H36




H37




H38




H39




H40




H41




H42




H43




H44




H45




H46




H47




H48




H49




H50




H51




H52




H53




H54

$R^{78}$ is H; lower alkyl; aryl; or aryl-lower alkyl;

$R^{78}$ and $R^{82}$ taken together can form: $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$;

$R^{79}$ is H; lower alkyl; aryl; or aryl-lower alkyl; or

$R^{78}$ and $R^{79}$, taken together, can be $-(CH_2)_{2-7}-$; $-(CH_2)_2O(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$;

$R^{80}$ is H; or lower alkyl;

$R^{81}$ is H; lower alkyl; or aryl-lower alkyl;

$R^{82}$ is H; lower alkyl; aryl; heteroaryl; or aryl-lower alkyl;

$R^{33}$ and $R^{82}$ taken together can form: $-(CH_2)_{2-6}-$; $-(CH_2)_2O(CH_2)_2-$; $-(CH_2)_2S(CH_2)_2-$; or $-(CH_2)_2NR^{57}(CH_2)_2-$;

$R^{83}$ is H; lower alkyl; aryl; or $-NR^{78}R^{79}$;

$R^{84}$ is $-(CH_2)_m(CHR^{61})_sOR^{78}$; $-(CH_2)_m(CHR^{61})_sSR^{78}$; $-(CH_2)_pCONR^{78}R^{79}$; $-(CH_2)_pNR^{80}CONR^{78}R^{79}$;
$-(CH_2)_pC_6H_4CONR^{78}R^{79}$; or $-(CH_2)_pC_6H_4NR^{80}CONR^{78}R^{79}$;

$R^{85}$ is lower alkyl; or lower alkenyl;

$R^{86}$ is $R^{74}$; $-[(CH_2)_u-X]_t-(CH_2)_vNR^{78}R^{79}$; $-[(CH_2)_u-X]_t-(CH_2)_v-C(=NR^{80})NR^{78}R^{79}$; X is -O-, $-NR^{20}-$, -S-, -OCOO-, u is 1-3, t is 1-6, v is 1-3;

$R^{87}$ is $R^{84}$; $-[(CH_2)_u-X]_t-(CH_2)_vOR^{78}$, $-[(CH_2)_u-X]_t-(CH_2)_v-CONR^{78}R^{79}$, $-[(CH_2)_u-X]_t-(CH_2)_v-NR^{80}CONR^{78}R^{79}$, $-[(CH_2)_u-X]_t-(CH_2)_v SR^{78}$; X is -O-, $-NR^{20}-$, -S-, -OCOO-, u is 1-3, t is 1-6, v is 1-3;

with the proviso that in said chain of 12 α-amino acid residues **Z** the amino acid residues in positions 1 to 12 are:

- P1: of type C or of type D or of type E or of type F, or the residue is Pro;
- P2: of type E or of type D;
- P3: of type C , or the residue is Pro;

- P4: of type E or of type F or of type I or of type K;
- P5: of type E or of type D or or of type C or of type I or of type K or of type F, or the residue is Gly or Pro;
- P6: of type E or of type F or of formula -A-CO-, or of type I or of type K or of type D, or the residue is Gly;
- P7: of type E or of type F or of type I or of type C or of formula -B-CO-;
- P8: of type D or of type C, or the residue is Pro;
- P9: of type E or of type D or of type F ;
- P10: of type D or of type C or the residue is Pro;
- P11: of type E or of type D or of type C; and
- P12: of type C or of type D or of type E or of type F, or the residue is Pro; or
- P4 and P9 and/or P2 and P11, taken together, can form a group of type H; and at P6 and P7 also D-isomers being possible;

with the further proviso that said chain of 12 α-amino acid residues contains at least one residue of type I or of type K;

and pharmaceutically acceptable salts thereof.

2-9. (Cancelled)

10. (Currently amended) Compounds according to claim ~~2~~ 1 wherein B is a group of formula $-NR^{20}CH(R^{71})-$ or an enantiomer ~~of one~~ of the groups A5 (with $R^2$ being H)~~;~~ or A8~~; A22; A25; A38 (with $R^2$ being H); A42; A47; and A50~~.

11. (Currently amended) Compounds according to claim ~~2~~ 1 wherein B-CO is Ala; Arg; Asn; Cys; Gln; Gly; His; Ile; Leu; Lys; Met; Phe; Pro; Ser; Thr; Trp; Tyr; Val; Cit; Orn; tBuA; Sar; t-BuG; 4AmPhe; 3AmPhe; 2AmPhe; Phe(mC($NH_2$)=NH; Phe(pC($NH_2$)=NH; Phe(mNHC

($NH_2$)=NH; Phe(pNHC ($NH_2$)=NH; Phg; Cha; $C_4$al; $C_5$al; Nle; 2-Nal; 1-Nal; 4Cl-Phe; 3Cl-Phe; 2Cl-Phe; 3,4$Cl_2$Phe; 4F-Phe; 3F-Phe; 2F-Phe; Tic; Thi; Tza; Mso; AcLys; Dpr; $A_2$Bu; Dbu; Abu; Aha; Aib; Y(Bzl); Bip; S(Bzl); T(Bzl); hCha; hCys; hSer, hArg; hPhe; Bpa; Pip; OctG; MePhe; MeNle; MeAla; MeIle; MeVal; MeLeu; BnG; (4-OH)BnG; IaG; IbG; (EA)G; (PrA)G; (BA)G; (PeA)G; (EGU)G; (PrGU)G; (BGU)G; (PeGU)G; ($PEG_3$-$NH_2$)G; (Et-$CONH_2$)G; (Et-OH)G; ($CH_2$-$CONH_2$)G; (n-Pr-$NHCONH_2$)G; or (Et-SH)G.

12. (Currently amended) Compounds according to claim ~~2~~ 1 wherein B is a group, having (L)-configuration, of formula




**A8''**

wherein $R^{20}$ is H; or lower alkyl; and $R^{64}$ is alkyl; alkenyl; aryl; aryl-lower alkyl; or heteroaryl-lower alkyl.

13. (Original) Compounds according to claim 12 wherein $R^{64}$ is n-hexyl; n-heptyl; 4-(phenyl)benzyl; diphenylmethyl, 3-amino-propyl; 5-amino-pentyl; methyl; ethyl; isopropyl; isobutyl; n-propyl; cyclohexyl; cyclohexylmethyl; n-butyl; phenyl; benzyl; (3-indolyl)methyl; 2-(3-indolyl)ethyl; (4-phenyl)phenyl; or n-nonyl.

14-15. (Cancelled)

16. (Previously presented) Compounds according to claim 1 wherein the α-amino acid residues in position 1 – 12 of chain Z are:

- P1: of type C or of type D or of type E or of type F,
- P2: of type D or of type E;
- P3: of type C;
- P4: of type E or of type I or of type F;
- P5: of type E or of type I or of type F;
- P6: of type E or of type I or of type D or of formula -A1-A69-CO;
- P7: of type E or of type I or of type C or of formula B-CO;
- P8: of type D;
- P9: of type E;
- P10: of type D or of type C,
- P11: of type E or of type D; or of type C and
- P12: of type C or of type D or of type E or of type F;
- at P6 and P7 also D-isomers being possible;

with the proviso that at least one of the amino acid residues is of type I.

17. (Original) Compounds according to claim 16 wherein the α-amino acid residues in position 1 – 12 of the chain Z are:

P1: Leu; Thr; or Arg;

- P2: Arg; or Trp;
- P3: Leu;
- P4: Lys; hArg; (BA)G; or Gln;
- P5: Lys; Gln; hArg; or (PeA)G;
- P6: Arg, Trp, hArg; (EGU)G;
  - (EA)G; (PrA)G; (PeA)G or (BA)G;
- P7: Arg; (PeA)G; or Val

- P8: Trp; or Bip;
- P9: Lys; Arg; or hArg;
- P10: Tyr;
- P11: Arg; or Tyr; and
- P12: Val; or Arg

with the proviso that

- the amino acid residue in P4 is (BA)G; and/or
- the amino acid residue in P5 is (PeA)G; and/or
- the amino acid residue in P6 is (EGU)G or (EA)G or (PrA)G or (PeA)G or (BA)G; and/or
- the amino acid residue in P7 is (PeA)G.

18. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (EA)G;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

19. (Original) A compound of formula Ia according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: hArg;
- P5: hArg;
- P6: (EGU)G;
- P7: Arg;
- P8: Trp;
- P9: hArg;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

20. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (PrA)G;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;

- P11: Arg; and
- P12: Val.

21. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro; and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (BA)G;
- P7: Arg;
- P8: Bip;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

22. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: (BA)G;
- P5: Lys;
- P6: (BA)G;
- P7: Arg;

- P8: Bip;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

23. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

- P1: Leu;
- P2: Arg;
- P3: Leu;
- P4: Lys;
- P5: Lys;
- P6: (PrA)G;
- P7: Arg;
- P8: Bip;
- P9: Lys;
- P10: Tyr;
- P11: Arg; and
- P12: Val.

24. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Lys;

- P5: Lys;
- P6: Arg;
- P7: (PeA)G;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Val.

25. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Gln;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Arg.

26. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Lys;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
- P12: Val.

27. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

P1: Thr;
- P2: Trp;
- P3: Leu;
- P4: Lys;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;
- P8: Trp;
- P9: Lys;
- P10: Tyr;

- P11: Tyr; and
  P12: Arg.

28. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

  P1: Arg;
- P2: Trp;
- P3: Leu;
- P4: Gln;
- P5: Lys;
- P6: Arg;
- P7: (PeA)G;
- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and
  P12: Arg.

29. (Original) A compound of formula I according to claim 1 wherein the template is $^{D}$Pro-$^{L}$Pro and the amino acid residues in position 1 – 12 are:

  P1: Thr;
- P2: Trp;
- P3: Leu;
- P4: Lys;
- P5: (PeA)G;
- P6: Arg;
- P7: Arg;

- P8: Trp;
- P9: Lys;
- P10: Tyr;
- P11: Tyr; and

  P12: Arg.

30. (Original) Enantiomers of the compounds of formula I as defined in claim 1.

31-32. (Cancelled)

33. (Previously presented) A pharmaceutical composition containing a compound according to claim 1 and a pharmaceutically inert carrier.

34. (Original) Compositions according to claim 33 in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, pulmonary or inhalation administration.

35. (Previously presented) Compositions according to claim 33 in form of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.

36. (Currently amended) ~~The use of compounds according to claim 1 for the manufacture of a medicament~~ A method for treating or preventing infections or diseases related to such infections, which comprises administering to a patient in need of such treatment or prevention an effective amount of a compound according to claim 1. ~~said disease being in particular Cystic Fibrosis.~~

37. (Currently amended) ~~The use of compounds according to claim 1 as disinfectants or preservatives for~~ A method for disinfecting or preserving foodstuffs, cosmetics, medicaments and other nutrient-containing materials which comprises adding to such foodstuffs, cosmetics, medicaments and other nutrient-containing materials an effective amount of a compound according to claim 1.

38. (Previously presented) A process for the manufacture of compounds according to claim 1 which process comprises

(a) coupling an appropriately functionalized solid support with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 5, 6 or 7, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(b) removing the N-protecting group from the product thus obtained;

(c) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position nearer the N-terminal amino acid residue, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(d) removing the N-protecting group from the product thus obtained;

(e) repeating steps (c) and (d) until the N-terminal amino acid residue has been introduced;

(f) coupling the product thus obtained with a compound of the general formula




II

wherein




is as defined above and X is an N-protecting group or, if




is to be group (a1) or (a2), above, alternatively

(fa) coupling the product obtained in step (e) with an appropriately N-protected derivative of an amino acid of the general formula

HOOC-B-H **III** or HOOC-A-H **IV**

wherein B and A are as defined above , any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(fb) removing the N-protecting group from the product thus obtained; and

(fc) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, III, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(g) removing the N-protecting group from the product obtained in step (f) or (fc);

(h) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is in position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(i) removing the N-protecting group from the product thus obtained;

(j) coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 12, any

functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(k) removing the N-protecting group from the product thus obtained;

(l) repeating steps (j) and (k) until all amino acid residues have been introduced;

(m) if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;

(o) detaching the product thus obtained from the solid support;

(p) cyclizing the product cleaved from the solid support;

(q) if desired, forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β-strand region;

(r) removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule;

(s) if desired guanidinylating any side-chain amino group present in the chain of amino acid residues; and

(t) if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.

39. (Previously presented) A process for the manufacture of compounds according to claim 1 which process comprises

(a') coupling an appropriately functionalized solid support with a compound of the general formula




II

wherein




is as defined above and X is an N-protecting group or, if




is to be group (a1) or (a2), above, alternatively

(a'a) coupling said appropriately functionalized solid support with an appropriately N-protected derivative of an amino acid of the general formula

HOOC-B-H **III** or HOOC-A-H **IV**

wherein B and A are as defined above , any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(a'b) removing the N-protecting group from the product thus obtained; and

(a'c) coupling the product thus obtained with an appropriately N-protected derivative of an amino acid of the above general formula IV and, respectively, III, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(b') removing the N-protecting group from the product obtained in step (a') or (a'c);

(c') coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position nearer the N-terminal amino acid residue, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(d') removing the N-protecting group from the product thus obtained;

(e') coupling the product thus obtained with an appropriately N-protected derivative of that amino acid which in the desired end-product is one position farther away from position 12, any functional group which may be present in said N-protected amino acid derivative being likewise appropriately protected;

(f') removing the N-protecting group from the product thus obtained;

(g') repeating steps (e') and (f') until all amino acid residues have been introduced;

(h') if desired, selectively deprotecting one or several protected functional group(s) present in the molecule and appropriately substituting the reactive group(s) thus liberated;

(i') detaching the product thus obtained from the solid support;

(j') cyclizing the product cleaved from the solid support;

(k') if desired forming one or two interstrand linkage(s) between side-chains of appropriate amino acid residues at opposite positions of the β-strand region;

(l') removing any protecting groups present on functional groups of any members of the chain of amino acid residues and, if desired, any protecting group(s) which may in addition be present in the molecule;

(m') if desired guanidinylating any side-chain amino group present in the chain of amino acid residues; and

(n') if desired, converting the product thus obtained into a pharmaceutically acceptable salt or converting a pharmaceutically acceptable, or unacceptable, salt thus obtained into the corresponding free compound of formula I or into a different, pharmaceutically acceptable, salt.

40. (Previously presented) A process according to claim 38 but wherein an amino acid residue of type I or K is introduced by coupling with a leaving group-containing acetylating agent, followed by nucleophilic displacement with an amine of the formula $H_2NR^{86}$ and, respectively, $H_2NR^{87}$ which, if necessary, is appropriately protected.

41. (Previously presented) A process according to claim 40 wherein said leaving group-containing acetylating agent is bromo, chloro or iodo acetic acid.

42. (Previously presented) A modification of the process according to claim 38 for the manufacture of compounds according to claim 30 in which enantiomers of all chiral starting materials are used.

43. (Previously presented) A process according to claim 39 but wherein an amino acid residue of type I or K is introduced by coupling with a leaving group-containing acetylating agent, followed by nucleophilic displacement with an amine of the formula $H_2NR^{86}$ and, respectively, $H_2NR^{87}$ which, if necessary, is appropriately protected.

44. (Previously presented) A process according to claim 43 wherein said leaving group-containing acetylating agent is bromo, chloro or iodo acetic acid.

45. (Previously presented) A modification of the process according to claim 39 for the manufacture of compounds according to claim 30 in which enantiomers of all chiral starting materials are used.

46. (New) A method according to claim 36 wherein said disease is Cystic Fibrosis.